Seaport Therapeutics IPO
Seaport Therapeutics is a clinical-stage biopharmaceutical company developing novel psychiatric medications to address mental health disorders. The company focuses on neuropsychiatry, an area of growing investor interest as mental health treatment approaches expand beyond traditional therapies.
Key Facts
| Industry | Biotechnology |
| Founded | 2020 |
| Headquarters | Boston, MA |
| Funding | Completed IPO in May 2026, raising $255M in an upsized offering priced at $18/share (high end of range). Began trading on Nasdaq under ticker SPTX on May 1, 2026, with shares up 17% on debut. |
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for psychiatric and neurological disorders. The company was founded by biopharma veterans including those with track records at companies like Axovant and other neuroscience-focused firms, bringing significant industry expertise to the venture.
The company's pipeline targets significant unmet needs in mental health treatment, where many patients experience inadequate responses to existing therapies or struggle with side effects. Seaport's drug candidates are designed to offer novel mechanisms of action that could provide improved efficacy, faster onset, or better tolerability compared to current standard-of-care options.
Seaport has raised funding from leading life sciences venture capital firms to advance its clinical programs through key milestones. The psychiatric drug market represents a substantial commercial opportunity, with conditions like major depressive disorder and generalized anxiety disorder affecting millions of patients globally and generating billions in annual pharmaceutical sales.
IPO Status
Seaport Therapeutics is advancing a pipeline of psychiatric drug candidates targeting conditions such as depression, anxiety, and potentially other neuropsychiatric disorders. The company was founded by prominent biopharma executives with experience in neuroscience drug development, bringing credibility to its scientific approach. In May 2026, Seaport Therapeutics successfully completed its initial public offering, raising $255 million through an upsized offering of shares priced at $18 per share (the high end of its $16-$18 range). The company began trading on the Nasdaq under the ticker symbol SPTX on May 1, 2026, with shares climbing 17% on their first day of trading. The company rang the opening bell at Nasdaq to mark its public debut. The successful IPO represents a significant milestone as the company seeks capital to advance its depression and anxiety drug pipeline. The mental health therapeutics sector continues to attract strong investor attention, as evidenced by the upsized offering and positive market reception.
Competitors
Frequently Asked Questions
Does Seaport Therapeutics have a stock?
Seaport Therapeutics has not yet had an IPO. The company remains private while advancing its clinical-stage psychiatric drug pipeline. Sign up for alerts to stay informed.
When is the Seaport Therapeutics IPO date?
No IPO date has been announced for Seaport Therapeutics. The timing would likely depend on clinical trial progress and market conditions for neuroscience-focused biotechs. Sign up for alerts to stay informed.
How can I buy Seaport Therapeutics stock?
Seaport Therapeutics stock is not currently available for purchase as the company is still private. Following an IPO, shares would trade on a public exchange through standard brokerage accounts. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts